| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
(±)-Leucine targets bacterial cells, exhibiting antibacterial activity. As an amino acid, it is also involved in protein synthesis and metabolic pathways. The compound's inhibition of E. coli growth suggests interaction with bacterial metabolic or transport systems.
|
|---|---|
| ln Vitro |
(±)-Leucine demonstrates in vitro antibacterial activity, inhibiting the growth of Escherichia coli HfrH by 92.08%. As a dietary additive and chemosterilant, it is used in various research applications. The compound is also used to study protein function and metabolic pathways.
|
| ln Vivo |
(±)-Leucine (DL-Leucine) boosts average catch by increasing the amount or frequency of female pheromone production [1].
In vivo activity of (±)-leucine is observed in its use as a dietary additive. As an essential amino acid, it plays a role in protein synthesis and metabolism in living organisms. Its antibacterial activity suggests potential for in vivo applications, but further studies are needed. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for (±)-leucine are not typically performed, as it is a basic amino acid rather than a pharmacologically active compound. Its effects on bacterial growth can be assessed using standard microbial growth inhibition assays.
|
| Cell Assay |
In vitro cellular assays for (±)-leucine involve culturing bacterial cells (e.g., E. coli HfrH) in the presence of varying concentrations of the compound. Antibacterial activity is assessed by measuring inhibition of growth using optical density measurements or colony counting.
|
| Animal Protocol |
In vivo animal experiments for (±)-leucine are typically related to its use as a dietary additive or in nutritional studies. The compound is administered in feed or by oral gavage, and its effects on growth, metabolism, or protein synthesis are evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (±)-leucine are consistent with its role as an amino acid. It is absorbed from the gastrointestinal tract and distributed throughout the body, participating in protein synthesis and metabolism. Its pharmacokinetic properties are typical of amino acids.
|
| Toxicity/Toxicokinetics |
Toxicological data for (±)-leucine indicate that it is generally safe at normal dietary levels. As an amino acid, it is a normal component of proteins and is well-tolerated. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Leucine is a branched-chain amino acid composed of glycine molecules, in which one hydrogen atom bonded to the α-carbon is replaced by an isobutyl group. It is a metabolite of the large flea (Daphnia magna). It is a branched-chain amino acid and also an α-amino acid. It contains an isobutyl group. It is the conjugate base of leucine. It is the conjugate acid of leucine. DL-leucine has been reported in Drosophila melanogaster, Populus tremula, and several other organisms with relevant data. See also: leucine (note moved to); D-leucine (note moved to).
(±)-Leucine (DL-Leucine; (RS)-Leucine) (CAS#: 328-39-2) has the molecular formula C6H13NO2 and a molecular weight of 131.18 g/mol. It is an endogenous metabolite and dietary additive. The compound inhibits E. coli growth by 92.08% and is used in research on protein function and metabolism. |
| Molecular Formula |
C6H13NO2
|
|---|---|
| Molecular Weight |
131.17
|
| Exact Mass |
131.094
|
| CAS # |
328-39-2
|
| Related CAS # |
(±)-Leucine-d10;29909-01-1;(±)-Leucine-d7;259225-40-6
|
| PubChem CID |
857
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
225.8±23.0 °C at 760 mmHg
|
| Melting Point |
293-296ºC
|
| Flash Point |
90.3±22.6 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.463
|
| LogP |
0.73
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
101
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ROHFNLRQFUQHCH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)
|
| Chemical Name |
2-amino-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
1M HCl : 50 mg/mL (381.18 mM)
H2O : 10 mg/mL (76.24 mM) DMSO : 1 mg/mL (7.62 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.6237 mL | 38.1185 mL | 76.2369 mL | |
| 5 mM | 1.5247 mL | 7.6237 mL | 15.2474 mL | |
| 10 mM | 0.7624 mL | 3.8118 mL | 7.6237 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
